Cargando…
Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib
Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental fa...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497038/ https://www.ncbi.nlm.nih.gov/pubmed/32064608 http://dx.doi.org/10.1002/ijc.32924 |
_version_ | 1783583230388076544 |
---|---|
author | Englinger, Bernhard Laemmerer, Anna Moser, Patrick Kallus, Sebastian Röhrl, Clemens Pirker, Christine Baier, Dina Mohr, Thomas Niederstaetter, Laura Meier‐Menches, Samuel M. Gerner, Christopher Gabler, Lisa Gojo, Johannes Timelthaler, Gerald Senkiv, Julia Jäger, Walter Kowol, Christian R. Heffeter, Petra Berger, Walter |
author_facet | Englinger, Bernhard Laemmerer, Anna Moser, Patrick Kallus, Sebastian Röhrl, Clemens Pirker, Christine Baier, Dina Mohr, Thomas Niederstaetter, Laura Meier‐Menches, Samuel M. Gerner, Christopher Gabler, Lisa Gojo, Johannes Timelthaler, Gerald Senkiv, Julia Jäger, Walter Kowol, Christian R. Heffeter, Petra Berger, Walter |
author_sort | Englinger, Bernhard |
collection | PubMed |
description | Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental factors affecting the activity of this compound are unknown. Cell/molecular biological and analytical chemistry methods were applied to investigate uptake kinetics/subcellular distribution, the role of lipid droplets (LDs) and lipoid microenvironment compartments in responsiveness of FGFR1‐driven lung cancer cells toward ponatinib. Selection of lung cancer cells for acquired ponatinib resistance resulted in elevated intracellular lipid levels. Uncovering intrinsic ponatinib fluorescence enabled dissection of drug uptake/retention kinetics in vitro as well as in mouse tissue cryosections, and revealed selective drug accumulation in LDs of cancer cells. Pharmacological LD upmodulation or downmodulation indicated that the extent of LD formation and consequent ponatinib incorporation negatively correlated with anticancer drug efficacy. Co‐culturing with adipocytes decreased ponatinib levels and fostered survival of cancer cells. Ponatinib‐selected cancer cells exhibited increased LD levels and enhanced ponatinib deposition into this organelle. Our findings demonstrate intracellular deposition of the clinically approved anticancer compound ponatinib into LDs. Furthermore, increased LD biogenesis was identified as adaptive cancer cell‐defense mechanism via direct drug scavenging. Together, this suggests that LDs represent an underestimated organelle influencing intracellular pharmacokinetics and activity of anticancer tyrosine kinase inhibitors. Targeting LD integrity might constitute a strategy to enhance the activity not only of ponatinib, but also other clinically approved, lipophilic anticancer therapeutics. |
format | Online Article Text |
id | pubmed-7497038 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-74970382020-09-25 Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib Englinger, Bernhard Laemmerer, Anna Moser, Patrick Kallus, Sebastian Röhrl, Clemens Pirker, Christine Baier, Dina Mohr, Thomas Niederstaetter, Laura Meier‐Menches, Samuel M. Gerner, Christopher Gabler, Lisa Gojo, Johannes Timelthaler, Gerald Senkiv, Julia Jäger, Walter Kowol, Christian R. Heffeter, Petra Berger, Walter Int J Cancer Cancer Therapy and Prevention Ponatinib is a small molecule multi‐tyrosine kinase inhibitor clinically approved for anticancer therapy. Molecular mechanisms by which cancer cells develop resistance against ponatinib are currently poorly understood. Likewise, intracellular drug dynamics, as well as potential microenvironmental factors affecting the activity of this compound are unknown. Cell/molecular biological and analytical chemistry methods were applied to investigate uptake kinetics/subcellular distribution, the role of lipid droplets (LDs) and lipoid microenvironment compartments in responsiveness of FGFR1‐driven lung cancer cells toward ponatinib. Selection of lung cancer cells for acquired ponatinib resistance resulted in elevated intracellular lipid levels. Uncovering intrinsic ponatinib fluorescence enabled dissection of drug uptake/retention kinetics in vitro as well as in mouse tissue cryosections, and revealed selective drug accumulation in LDs of cancer cells. Pharmacological LD upmodulation or downmodulation indicated that the extent of LD formation and consequent ponatinib incorporation negatively correlated with anticancer drug efficacy. Co‐culturing with adipocytes decreased ponatinib levels and fostered survival of cancer cells. Ponatinib‐selected cancer cells exhibited increased LD levels and enhanced ponatinib deposition into this organelle. Our findings demonstrate intracellular deposition of the clinically approved anticancer compound ponatinib into LDs. Furthermore, increased LD biogenesis was identified as adaptive cancer cell‐defense mechanism via direct drug scavenging. Together, this suggests that LDs represent an underestimated organelle influencing intracellular pharmacokinetics and activity of anticancer tyrosine kinase inhibitors. Targeting LD integrity might constitute a strategy to enhance the activity not only of ponatinib, but also other clinically approved, lipophilic anticancer therapeutics. John Wiley & Sons, Inc. 2020-03-02 2020-09-15 /pmc/articles/PMC7497038/ /pubmed/32064608 http://dx.doi.org/10.1002/ijc.32924 Text en © 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Cancer Therapy and Prevention Englinger, Bernhard Laemmerer, Anna Moser, Patrick Kallus, Sebastian Röhrl, Clemens Pirker, Christine Baier, Dina Mohr, Thomas Niederstaetter, Laura Meier‐Menches, Samuel M. Gerner, Christopher Gabler, Lisa Gojo, Johannes Timelthaler, Gerald Senkiv, Julia Jäger, Walter Kowol, Christian R. Heffeter, Petra Berger, Walter Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib |
title | Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib |
title_full | Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib |
title_fullStr | Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib |
title_full_unstemmed | Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib |
title_short | Lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib |
title_sort | lipid droplet‐mediated scavenging as novel intrinsic and adaptive resistance factor against the multikinase inhibitor ponatinib |
topic | Cancer Therapy and Prevention |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497038/ https://www.ncbi.nlm.nih.gov/pubmed/32064608 http://dx.doi.org/10.1002/ijc.32924 |
work_keys_str_mv | AT englingerbernhard lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT laemmereranna lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT moserpatrick lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT kallussebastian lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT rohrlclemens lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT pirkerchristine lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT baierdina lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT mohrthomas lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT niederstaetterlaura lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT meiermenchessamuelm lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT gernerchristopher lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT gablerlisa lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT gojojohannes lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT timelthalergerald lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT senkivjulia lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT jagerwalter lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT kowolchristianr lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT heffeterpetra lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib AT bergerwalter lipiddropletmediatedscavengingasnovelintrinsicandadaptiveresistancefactoragainstthemultikinaseinhibitorponatinib |